Anatara Lifesciences Expands GaRP-IBS Clinical Trial Sites to Adelaide and Sunshine Coast, Drives Record Enrollments
Anatara Lifesciences (ASX: ANR), a developer of gastrointestinal health solutions, is pleased to announce robust progress in recruitment for Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.